Denmark's Genmab hits the jackpot with $500M+ US IPO as smaller biotechs rake in a combined $147M

Danish drugmaker Genmab A/S is off to the races with perhaps one of the biggest biotech public listings in decades, having reaped over $500 million on the Nasdaq, as it positions itself as a bonafide player in antibody-based cancer therapies.